In a major advance for WM patients, the NCCN guidelines committee voted to include ibrutinib, a recently FDA approved oral medication to the options for therapy for WM patients who have previously been treated and are in need of therapy. The decision was based on a Phase II study in WM patients that was conducted by Drs. Steve Treon (DFCI), Ranjana Advani (Stanford) and Lia Palomba (Memorial Sloane) and presented at the American Society of Hematology meeting in December, 2013. NCCN guidelines are used by Medicare and many insurers to determine off-label coverage for oncology drugs.